Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054612 | 0.93 | CSF1R (0.47) | CSF1RKCNH2SCN5ANUDT1 | |
| SCHEMBL2749299 | 0.86 | CSF1R (0.64) | CSF1RNUDT1 | |
| SCHEMBL15054886 | 0.83 | CSF1R (0.46) | CSF1RENPP1NUDT1 | |
| SCHEMBL2724559 | 0.82 | CSF1R (0.58) | CSF1RNUDT1 | |
| SCHEMBL15054702 | 0.82 | CSF1R (0.45) | CSF1R | |
| SCHEMBL5929884 | 0.80 | CSF1R (0.56) | CSF1RNUDT1 | |
| SCHEMBL8326185 | 0.79 | SLC2A1 (0.40) | CSF1RKCNH2SCN5A | |
| SCHEMBL15054656 | 0.79 | CSF1R (0.45) | CSF1RNUDT1 | |
| SCHEMBL5929785 | 0.79 | NNMT (0.46) | CSF1RKCNH2 | |
| SCHEMBL5929634 | 0.79 | CSF1R (0.57) | CSF1RNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| CN-1942445-A | Novel quinoline-carbaxamides as JACK3 kinase modulators | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| EP-1718615-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075429-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | JAK3, JAK1, JAK2 | CSF1R 626/4885KCNH2 537/4885SCN5A 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.